EAST RUTHERFORD, N.J., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the second quarter 2017.
Highlights
•Net Revenue increased 13% to $134.6 million compared to $118.6 million in the same quarter last year. Excluding the impact of foreign exchange, net revenue increased 15%.
